Natriuretic Peptides as a Novel Target in Resistant Hypertension

Current Hypertension Reports

Volumn 17, Issue 4, 2015, Pages

  Patel, Pratik ^a   Chen, Horng H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic kidney diseases; Natriuretic peptides; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; NATRIURETIC FACTOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; HEMODYNAMICS; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGNOSIS; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; HOMEOSTASIS; HYPERTENSION; PATHOLOGY; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; HOMEOSTASIS; HUMANS; HYPERTENSION; NATRIURETIC PEPTIDES; PROGNOSIS; RISK FACTORS;

EID: 84924678469     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0530-0     Document Type: Review

References (71)

1. Calhoun DA et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension. 2008;51(6):1403–19.
2. Cushman WC et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.
3. Tanner RM et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol CJASN. 2013;8(9):1583–90. This study describes the prevalence of resistant hypertension in patients with chronic kidney disease.
4. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076–80. This study describes the prevalence of resistant hypertension in large U.S. population.
5. Egan BM et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58. This study describes the prevalence of resistant hypertension a diverse U.S. population.
6. Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.
7. Weinberger MH et al. Dietary sodium restriction as adjunctive treatment of hypertension. JAMA. 1988;259(17):2561–5.
8. Henningsen NC et al. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand. 1980;207(4):245–51.
9. Lloyd-Jones DM et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594–9.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.
11. Ho H et al. Association between the CYP3A5 genotype and blood pressure. Hypertension. 2005;45(2):294–8.
12. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216–24.
13. Gupta AK et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004–13.
14. de Haro Moraes C et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225–30.
15. Papademetriou V et al. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014;129(13):1440–51.
16. Tsioufis C et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416.
17. Gaddam KK et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159–64.
18. De Nicola L et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61(24):2461–7.
19. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.
20. Garg JP et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5 Pt 1):619–26.
21. Materson BJ et al. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Journal of human hypertension, 1995. 9(10): p. 791–6.
22. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.
23. Cody RJ et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78(5):1362–74.
24. Burnett Jr JC, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247(5):F863–6.
25. Schirger JA et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000;35(3):796–801.
26. Brunner-La Rocca HP et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37(5):1221–7.
27. Yamamoto K, Burnett Jr JC, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273(5 Pt 2):H2406–14.
28. Kasama S et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008;29(12):1485–94.
29. Tsuruda T et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91(12):1127–34.
30. Kario K et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705. This study showed that LCZ696 led to better blood pressure control in Asian patients compared with an ARB.
31. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132(5):1961–70.
32. Rubattu S et al. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med. 2010;88(9):889–97.
33. Chen HH, Burnett Jr JC. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998;32 Suppl 3:S22–8.
34. Gaspari TA et al. Type-C natriuretic peptide prevents development of experimental atherosclerosis in rabbits. Clin Exp Pharmacol Physiol. 2000;27(8):653–5.
35. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26(6):1044–59.
36. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(1):83–8.
37. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res. 2001;51(3):450–62.
38. Lisy O et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37(4):1089–94.
39. Lisy O et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52(1):60–8.
40. Hodgson-Zingman DM et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008;359(2):158–65.
41. McKie PM, Ichiki T, Burnett Jr JC. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14(1):62–9. This review paper describes MNAP, a novel ANP-based peptide and its potential for a novel agent to treat hypertension.
42. Newton-Cheh C et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53.
43. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7.
44. John SW et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81.
45. Campese VM et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28(3):335–40.
46. Macheret F et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60(16):1558–65.
47. Xue H et al. Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci. 2008;114(2):131–7.
48. Knappe S et al. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem. 2003;278(52):52363–70.
49. Dries DL et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112(16):2403–10.
50. Suwa M et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J Off J Japan Circ Soc. 2005;69(3):283–90.
51. Colucci WS et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246–53.
52. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002. 287(12): p. 1531–40.
53. Williams B et al. Rationale and study design of the prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open. 2014;4(2):e004254.
54. Lee CY et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49(6):668–73.
55. Kousholt BS. Natriuretic peptides as therapy in cardiac ischaemia/reperfusion. Dan Med J. 2012;59(6):B4469.
56. Therrien JP et al. A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts. Proc Natl Acad Sci U S A. 2010;107(3):1178–83.
57. McKie PM et al. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009;54(11):1024–32.
58. McKie PM et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010;56(6):1152–9.
59. McKie PM et al. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014;3(1):e000206. This in vivo study of a canine model of hypertensive heart failure showed M-ANP administration led to reduction in mean arterial pressure.
60. Lazzeri C et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am J Hypertens. 1995;8(8):799–807.
61. Franco-Saenz R, Somani P, Mulrow PJ. Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension. Am J Hypertens. 1992;5(5 Pt 1):266–75.
62. Singer DR et al. Prolonged decrease in blood pressure after atrial natriuretic peptide infusion in essential hypertension: a new anti-pressor mechanism? Clin Sci. 1989;77(3):253–8.
63. Zhang WG et al. Effects of atrial natriuretic factor on patients with renovascular hypertension. Chin Med J. 1992;105(9):732–7.
64. Predel HG et al. Atrial natriuretic peptide in patients with essential hypertension. Hemodynamic, renal, and hormonal responses. Am J Hypertens. 1991;4(11):871–9.
65. Cusson JR et al. Prolonged low dose infusion of atrial natriuretic factor in essential hypertension. Clin Exp Hypertens Part A Theory Prac. 1990;12(1):111–35.
66. Burnier M et al. Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome. J Cardiovasc Pharmacol. 1989;13(5):682–90.
67. Cataliotti A et al. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin Proc. 2012;87(4):413–5.
68. Bevan EG et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607–13.
69. Richards AM et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11(4):407–16.
70. Ruilope LM et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.
71. McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. This randomized,double blinded, placebo controlled study showed angiotensin receptor -neprilysin inhbitor led to better outcomes compared with ace inhibitor in patients with systolic heart failure.